On one hand, it enhances the predictability of survival outcomes in ccRCC patients; on the other hand, the six nc-MTGs (BID, FKBP10, PRELID2, FDXR, POLG2, and ACADM) within this feature can also assess the immune status and immune checkpoints of ccRCC patients. Here, ACADM is linked to nonpapillary renal cell carcinoma.